B
iologic therapy with tumor necrosis factor (TNF)-a inhibitor agents, such as infliximab and adalimumab, alone or in combination with immunomodulators, is one of the most effective treatments in inducing and maintaining clinical remission in patients with ulcerative colitis (UC), and has been shown to decrease risk of hospitalization and surgery. [1] [2] [3] [4] In the absence of head-to-head trials, there is an unmet need among patients and physicians to better understand the relative effectiveness and safety of different TNF-a inhibitors. Current decisions on the choice of TNF-a inhibitor are primarily driven by patient and clinician preferences, and in some countries, on insurance coverage; however, there are differences in the molecular construct, dosing, and route of administration of these agents, and hence, there may be differences in effectiveness and safety. 5 Indirect treatment comparison network metaanalysis has suggested that in a subset of biologicnaive patients with UC, infliximab may be superior to adalimumab for induction of clinical response and mucosal healing, but comparable for maintenance of remission. 6, 7 However, these short-term trials had restrictive inclusion criteria, and hence, had limited generalizability. In contrast, observational comparative effectiveness studies using health claims administrative databases and retrospective chart review have observed no significant differences in rates of hospitalization or clinical remission between infliximab-and adalimumabtreated patients. 8, 9 These data are limited by potential misclassification of prior TNF-a inhibitor exposure, low event rates with inability to comment on differences in risk of surgery or serious infections, and inadequate adjustment for disease severity and other confounders.
Therefore, to overcome these limitations, we studied the comparative effectiveness and safety of infliximab and adalimumab in biologic-naive adults with UC, using a population-based, propensity score-matched cohort study from the Danish nationwide registry. Using patientimportant outcomes of all-cause and UC-related hospitalizations, abdominal surgery, need for corticosteroids, and risk of serious infections, in a biologic-naive population, the results of this study might assist consumers, clinicians, purchasers, and policy makers to make informed decisions that improve health care in inflammatory bowel disease (IBD) at the individual and the population level.
Methods

Data Sources
The source population consisted of all individuals 15 years or older and living in Denmark between 2005 and 2014 according to the Danish Civil Registration System. 10 Using the unique personal identification number given to each Danish citizen at birth, the population was linked to the National Patient Registry, which contains information on all hospitalizations in Denmark since 1977 and all outpatient visits and emergency department contacts since 1995. 11 In the National Patient Registry, we identified patients with IBD using International Classification of Diseases (ICD) codes (ICD-8 codes 56300-02 and 56308-09, and ICD-10 code K50 for Crohn's disease; ICD-8 codes 56319 and 56904, and ICD-10 code K51 for UC). Using a pathology database as reference, an assessment of nearly 800 patients estimated the completeness of registration of IBD in the National Patient Registry to be 94%, whereas the estimated validity, expressed as the proportion of confirmed diagnoses in the registry, was 97% for Crohn's disease and 90% for UC. 12 Information on prescription of infliximab and adalimumab was obtained using procedure codes (BOHJ18A1, BOHJ18A3) from the Danish Ministry of Health and Danish Drug Prescription Registry (ATC code L04AB04). Although the treatment with TNF-a inhibitors for IBD was introduced in Denmark in 1999, we started the study in 2005 and excluded people who used TNF-a inhibitors before the start of the study; in this way, early drug users who may have been treated in the first years after the introduction of TNF-a inhibitors (who are likely to be different from the drugs' eventual stable user population, in terms of such factors as disease severity and therefore may introduce bias) were excluded. We also excluded patients with a concomitant diagnosis of rheumatoid arthritis, ankylosing spondylitis, psoriasis, or psoriatic arthritis, as competing causes for prescribing TNF-a inhibitors. In case a patient received diagnostic codes for both UC and Crohn's disease, then the patient was classified as having UC if the most recent diagnosis was UC. Golimumab was not approved for commercial use in moderate to severe UC until May 2013; therefore, we did not have sufficient data on the use of this TNF-a inhibitor in our cohort. Figure 1 shows the flow of patients for identification of the cohort.
The study was approved by the Danish Data Protection Agency. Ethics approval is not required for registrybased research in Denmark.
Exposures and Outcomes of Interest
The primary exposures of interest were prescription of infliximab or adalimumab for UC. We considered patients as being continuously exposed from the index date (date of first registration of TNF-a inhibitor) for the duration of their prescription. Patients were followed until occurrence of the outcome of interest (discussed later), treatment discontinuation or switching (absence of new registration for a period of >4 months [for infliximab] or >3 months [for adalimumab], either discontinuing all TNF-a inhibitors or switching to another TNF-a inhibitor), death, or completion of the study (last date of follow-up, December 31, 2014).
The primary outcomes of interest were effectiveness outcomes and safety outcomes. Effectiveness outcomes include (1) all-cause hospitalization; (2) UC-related hospitalization, with UC either as the primary diagnosis, or as a secondary diagnosis if the primary diagnosis was related to a gastrointestinal symptom (abdominal pain, diarrhea, nausea, vomiting, constipation, gastrointestinal bleeding); (3) colectomy (identified using established procedural codes) 13 ; and (4) corticosteroid prescription, occurring at least 60 days after the start of anti-TNF therapy (to minimize confounding by disease severity). Safety outcomes include hospitalization for serious infections as primary diagnosis (Supplementary Table 1). 14 If the index TNF-a inhibitor was started during an inpatient hospitalization, then that hospitalization was not counted as an outcome; only inpatient admissions occurring >23 hours after drug initiation were regarded as outcomes (to avoid misclassifying observation visits for infliximab infusions as outcome).
Covariates of Interest
Independent variables of interest included measures of health care utilization, surrogate markers of disease severity, and use of IBD-related medications, in the baseline period (before initiation of the index anti-TNF agent). We assessed baseline health care utilization based on the number of all-cause hospitalizations, emergency department visits, endoscopic procedures (upper endoscopy, colonoscopy, sigmoidoscopy, capsule endoscopy) identified via Current Procedural Terminology codes, and abdominal/pelvic radiologic procedures (magnetic resonance imaging, computed tomography, small bowel follow-through, barium enemas) in the preceding 12 months. Although we did not have access to individual participant data medical records, endoscopy reports, or biochemical parameters, we modified an existing score for "disabling" Crohn's disease by Beaugerie et al. 15 Patients were classified as disabling UC if they had any 2 of following since UC diagnosis, before initiation of TNF-a inhibitor: need for >2 course of corticosteroids since UC diagnosis, need for abdominal surgery, UC-related hospitalization, and/or use of immunosuppressive medications. We evaluated UC-related medication use in the baseline 3 and 12 months including use of 5-aminosalicylates (mesalamine, sulfasalazine, balsalazide, olsalazine), oral corticosteroids (prednisone, budesonide), immunomodulators (azathioprine, 6-mercaptopurine, methotrexate), other immunosuppressive medications (tacrolimus, cyclosporine, mycophenolate mofetil), and use of narcotic pain medications.
Patients were classified as being on concomitant therapy with immunomodulators (TNF-a inhibitor-based combination therapy) if they received immunomodulator prescriptions within 30 days before and/or after TNF-a inhibitor index start date. 16 Based on corticosteroid use, patients were classified as remote users (if they received prescriptions for corticosteroids in the preceding 90 to 365 before index TNF-a inhibitor start date, but not within 90 days before start of TNF-a inhibitor), and recent users (if they received prescriptions for corticosteroids in the preceding 90 days before index TNF-a inhibitor start date).
Statistical Analysis
To take into account potential confounders we used variable 2:1 propensity score matching using the nearest neighbor caliper matching with a caliper width of 0.2. 17 We calculated the propensity scores as the predicted probability of starting treatment with TNF-a inhibitors conditional on variables thought to be either confounders or predictors for the outcome. These variables included demographic variables (age at initiation of TNF-a inhibitor, sex), disease-related characteristics (age at disease onset, disease duration, prior abdominal surgery), disease severity, measures of health care utilization (all-cause or UC-related outpatient visit, emergency department visit or hospitalization, endoscopy and/or radiology procedure within preceding 5 years), comorbidity burden (based on Charlson-Deyo index 18 ), and medication use (all and IBD-related) (Supplementary Table 2 ). We measured the standardized difference of each covariate in the propensity score model using logistic regression, and variables were considered to be different across treatment if after propensity score matching the standardized difference was greater than 10%.
We estimated hazard ratios (HR) with 95% confidence intervals (CI) for each outcome of interest separately using time since first TNF-a inhibitor treatment as underlying time-scale, and patients were censored at time of treatment discontinuation or switching (to another TNF-a inhibitor) or death or end of observation period. Analyses were carried out using Phreg procedure in SAS version 9.4 (Cary, NC). We considered differences to be statistically significant when the 95% CI did not overlap 1.0 or when the P value was < .05 (all tests were 2-sided).
Sensitivity Analyses
We performed stratified analysis based on use of TNF-a inhibitor monotherapy or combination therapy (concomitant use of immunomodulators), and by sex. Because of potential for incomplete adjustment for confounders, we performed a sensitivity analysis using an array approach suggested by Schneeweiss. 19 In this approach, if an incompletely measured (eg, disease severity based on clinical disease activity indices or endoscopic measures, not captured in our cohort) or unmeasured confounder (eg, smoking) may preferentially result in prescription of one agent over another, and may influence risk of outcomes, then we can infer the probable relationship between the 2 agents in different scenarios of confounder distribution. Additional post hoc sensitivity analyses suggested during the peer review stage were performed, based on restricting to patients who were prescribed TNF-a inhibitor in or after 2012 (because adalimumab was approved for UC only in 2012), and restricting to patients classified as having disabling disease based on surrogate measures captured in the modified Beaugerie index.
Results
Characteristics of Patients
We identified 1719 biologic-naive patients with UC who started their first anti-TNF agent between 2005 and 2014, of whom 139 were treated with adalimumab and 1580 with infliximab. After propensity score matching the cohort was restricted to 104 patients treated with adalimumab and 171 patients with infliximab (C statistic, 0.77), and their baseline demographic, clinical, treatment characteristics, and health care utilization were comparable (Table 1, Supplementary Table 3) . Median disease duration before starting TNF-a inhibitor was 3.3 years for adalimumab-and 3.9 years for infliximab-treated patients. About 24% patients were classified as having severe disease; 40% patients received recent steroids, and 48% patients were on concomitant immunomodulators at time of TNF-a inhibitor initiation.
Comparative Effectiveness of Adalimumab Versus Infliximab
As compared with infliximab-treated patients, adalimumab-treated patients had higher risk of all-cause hospitalization (HR, 1.84; 95% CI, 1.18-2.85), and trend toward increased risk of UC-related hospitalization (HR, 1.71; 95% CI, 0.95-3.07) ( Table 2 ). Twenty-eight patients underwent coloectomy after starting TNF-a inhibitor, and there was no significant difference in the risk of surgery (adalimumab vs infliximab: HR, 1.35; 95% CI, 0.62-2.94). Similarly, there was no difference in the risk of new corticosteroid prescription between adalimumaband infliximab-treated patients.
On stratified analysis by TNF-a inhibitor monotherapy and concomitant immunomodulator therapy, significant differences in the risks of all-cause and UCrelated hospitalization were observed between adalimumab-and infliximab-treated patients in a subset of patients on concomitant immunomodulator therapy, but not in patients on TNF-a inhibitor monotherapy (Table 3) . On separate stratified analysis by sex, males were more likely to have higher risks of all-cause and UC-related hospitalization with adalimumab as compared with infliximab, but no significant differences were observed in females (Supplementary Table 4 ).
On sensitivity analyses restricted to patients prescribed adalimumab or infliximab in or after 2012, and on restricting to patients classified as having disabling disease based on the modified Beaugerie index, similar results were performed: adalimumab-treated patients had higher risk of all-cause and UC-related hospitalization, as compared with infliximab-treated patients (Table 4 ). On sensitivity analyses using an array approach, assuming that patients with clinically severe disease (based on disease activity indices) were more likely to be prescribed infliximab as compared with adalimumab (considering its use as rescue therapy in acute severe colitis), 20 the observed point estimate for UC-related hospitalization (HR, 1.71) and surgery (HR, 1.35), would have been biased by 24% and 21%, respectively, and the confounder-adjusted estimate would be 2.1 and 1.7 for adalimumab versus infliximab, respectively (Supplementary Table 5 ).
Comparative Safety of Adalimumab Versus Infliximab
In propensity score-matched analysis, as compared with infliximab-treated patients, adalimumab-treated patients had a higher risk of serious infections (HR, 5.11; 95% CI, 1.20-21.80), although the number of events was small (n ¼ 8) (Table 2) . No opportunistic infections were observed. On stratified analysis, all serious infections were observed in patients on TNF-a inhibitor monotherapy (Table 3) . On specifically evaluating these 8 patients, 4 patients were on concomitant steroids at start of anti-TNF (3 of 5 adalimumab-treated patients, 1 of 3 infliximab-treated patients), and 4 patients were classified as having disabling UC (2 of 5 adalimumab-treated patients, 2 of 3 infliximab-treated patients). Seven patients were on corticosteroids at time of serious infection (4 of 5 adalimumab-treated patients, 3 of 3 infliximab-treated patients).
Discussion
Although TNF-a-inhibitor-based therapy is one of the most effective treatments for UC, there are limited data on the comparative effectiveness and safety of different agents. In this Danish nationwide cohort study of 1719 biologic-naive patients with UC (104 patients treated with adalimumab and 171 patients with infliximab, in propensity score-matched cohort), we observed that adalimumab was associated with a higher risk of allcause hospitalization and showed a trend toward higher risk of UC-related hospitalization, as compared with infliximab; the risks of surgery and new corticosteroid initiation were comparable. This difference in effectiveness was most pronounced in patients on concomitant immunomodulator monotherapy, and in males. These findings were persistent, with higher summary estimates, on sensitivity analyses restricted to patients treated with TNF-a inhibitors in or after 2012 (when adalimumab was approved for UC), and to patients classified as having disabling disease based on modified Beaugerie index. We also observed that adalimumab use was associated with a higher risk of serious infections as compared with infliximab, but these results were based on small number of outcome events. Based on findings from this population-based, propensity score-matched contemporary cohort of patients with UC, infliximab seems to be more effective and safer as compared with adalimumab for key patient-related effectiveness and safety outcomes for treatment of UC.
Our results are consistent with findings from indirect treatment comparison network meta-analyses, which have suggested that in a subset of biologic-naive patients with UC, infliximab may be superior to adalimumab for induction of clinical response and mucosal healing, but comparable for maintenance of remission. 6, 7 However, network meta-analysis is limited by lack of head-to-head trials; limited long-term follow-up; restrictive inclusion criteria in registration trials; and lack of data on patientimportant outcomes, such as hospitalization, surgery, and serious infections.
There have been a limited number of observational studies on the comparative effectiveness of different TNF-a inhibitors in UC. In a United States administrative claims-based retrospective analysis of 1400 patients with UC, we had previously observed no significant differences in the risk of hospitalization and serious infections between infliximab-and adalimumab-treated patients; however, infliximab-treated patients had lower risk of corticosteroid use and were more likely to remain on index TNF-a inhibitor at 6 and 12 months. 8 However, the study was limited by small number of surgical events, potential misclassification of biologicnaive patients, and inability to account for unmeasured confounders particularly disease severity. In another retrospective multisite cohort study in which 170 physicians reported on 6-month outcomes of biologic-naive infliximab-(n ¼ 380) or adalimumab-treated (n ¼ 424) patients with UC from their practices, there were no significant differences in clinical response (based on physician global assessment), health care use, and partial Mayo score. 9 This observed superiority of infliximab over adalimumab has also been observed in patients with Crohn's disease. In an administrative claims-based study on 3205 patients with Crohn's disease, we observed that infliximab-treated patients had a lower risk of Crohn's disease-related hospitalization (HR, 0.80; 95% CI, 0.66-0.98), abdominal surgery (HR, 0.76; 95% CI, 0.58-0.99), and corticosteroid use (HR, 0.85; 95% CI, 0.75-0.96). 16 In the US Medicare retrospective cohort study of patients with Crohn's disease, among patients younger than 65 years, Osterman et al 21 also observed that infliximab use was associated with a lower risk of surgery compared with adalimumab (adjusted odds ratio, 0.66; 95% CI, 0.47-0.93).
Despite both TNF-a inhibitors having a similar mechanism of action, there are subtle differences in pharmacokinetics, which may explain differences in effectiveness. Infliximab administered intravenously is dosed based on body weight, whereas adalimumab is a fixed-dose drug, administered subcutaneously, resulting in different bioavailability. Obesity has been shown to modify drug clearance and treatment response, [22] [23] [24] and with 20%-40% of patients with IBDs now being obese, differential effectiveness of these agents in obese patients may have contributed to observed differences. [25] [26] [27] In a retrospective cohort study, Bhalme et al 28 observed higher need for dose escalation because of therapeutic failure in obese patients with Crohn's disease treated with adalimumab but not infliximab. The cause for observed differences in safety of infliximab and adalimumab is unclear. There were no differences between infliximab-and adalimumab-treated patients in known factors that may contribute to increased risk of infections, such as age, baseline disease severity, concomitant use of immunomodulators, corticosteroids, and narcotics. 29 It is possible that by offering superior disease control and lower rates of hospitalization, infliximab-treated patients may have lower susceptibility to infections, particularly hospital-acquired infections.
Our findings, favoring infliximab over adalimumab, were significant in a stratum of patients on concomitant immunomodulator therapy. Generally, patients with more severe disease, or those who have failed immunomodulator monotherapy (and hence, inherently more treatment resistant) are treated with the combination of TNF-a inhibitors and immunomodulators. So, patients on concomitant immunomodulator therapy may represent more severe cases, where infliximab may be more effective than adalimumab; in patients with moderate disease, who may be treated with TNF-a inhibitor monotherapy, both medications were observed to have comparable effectiveness. Similarly, we observed that infliximab was superior to adalimumab in a stratum of male patients, but not in females. It is unclear why this was observed. Pharmacokinetic studies suggest more rapid drug clearance in males as compared with females, and this may preferentially impact clearance of fixeddose agent, such as adalimumab, as compared with weight-based medications, such as infliximab. The finding of all 8 serious infections being observed in patients on TNF-a inhibitor monotherapy, with no event observed in the TNF-a inhibitor combination therapy group, was counterintuitive. However, we observed that 7 (out of 8) patients were on corticosteroids at time of serious infection, which may have increased risk of infections even in the absence of concomitant use of immunomodulators.
These findings must be interpreted with caution, given the limitations associated with our study design. First, this was an observational, not an interventional study, and hence, there may be unmeasured confounders across groups. The potential for unmeasured confounding by severity is of particular importance, because we were not able to objectively assess endoscopic or biochemical disease activity. However, the effect of this in our analysis is probably minimal. The overall prevalence of measures of disabling UC was comparable between adalimumab-and infliximab-treated patients. Also, because patients with more severe disease, including those with acute severe colitis, may preferentially be recommended infliximab over adalimumab, the results are likely to be biased results against infliximab, unlike what was observed in our analysis. We tried to ascertain the magnitude of this impact through an array sensitivity analysis, which confirmed our findings. Second, we were unable to account for the impact of therapeutic drug monitoring or dose escalation, practices that have become more common recently, given inaccurate estimation using administrative databases. Third, both baseline covariates and outcomes were measured using administrative claims codes and may be subject to errors. Definitions for some covariates and outcomes, such as combination immunosuppressive therapy and treatment discontinuation, were chosen using best investigator judgment, and have not been validated.
In conclusion, using a population-based, propensitymatched cohort study, we observed that infliximab may be more effective and safer than adalimumab in biologicnaive patients with UC. With the advent of biosimilars, with similar effectiveness of their originator compound, this information may enable informed decision-making in choosing TNF-a inhibitors in biologic-naive patients with UC.
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